Legal & General Group’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Legal & General Group’s Portfolio KLDO Stock Details KLDO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,885	Closed	-$3K	–	3769
2022 Q1	$3K	Hold	1,885	–	–	﹤0.01%	3546
2021 Q4	$4K	Hold	1,885	–	–	﹤0.01%	3559
2021 Q3	$10K	Hold	1,885	–	–	﹤0.01%	3451
2021 Q2	$14K	Buy	1,885 +480	+34%	+$3.4K	﹤0.01%	3395
2021 Q1	$11K	Hold	1,405	–	–	﹤0.01%	3364
2020 Q4	$13K	Hold	1,405	–	–	﹤0.01%	3262
2020 Q3	$16K	Sell	1,405 -102	-7%	-$706	﹤0.01%	3062
2020 Q2	$11K	Sell	1,507 -132	-8%	-$885	﹤0.01%	3297
2020 Q1	$10K	Sell	1,639 -476	-23%	-$3.11K	﹤0.01%	3171
2019 Q4	$11K	Buy	2,115 +1,247	+144%	+$7.92K	﹤0.01%	3287
2019 Q3	$7K	Hold	868	–	–	﹤0.01%	3310
2019 Q2	$10K	Buy	+868	New	+$12.6K	﹤0.01%	3367

Other funds holding KLDO

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Legal & General Group's KLDO Position: Q2 2022 in Review

Legal & General Group sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2022, closing a stake of 1,885 shares — an estimated $3K sold.

Legal & General Group first reported a position in KLDO in Q2 2019 and held it in 12 quarters. The position peaked at $16K in Q3 2020. 3 funds tracked by Wall St. Rank hold KLDO as of Q2 2022.

Legal & General Group reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Legal & General Group sold 1,885 Kaleido Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $3K.
Legal & General Group first reported a position in Kaleido Biosciences, Inc. Common Stock in Q2 2019 and held it in 12 quarters.
Legal & General Group's Kaleido Biosciences, Inc. Common Stock position peaked at $16K in Q3 2020.
3 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2022.

Based on Legal & General Group's 13F filing for Q2 2022, filed 22 Aug 2022.